Trial Profile
A Phase 2, Multi-site, Randomized, Double-blind, Vehicle-controlled Study of the Efficacy and Safety of Squaric Acid Dibutyl Ester (SADBE) in Subjects With Recurrent Herpes Labialis - Single Versus Two-dose Arm Application
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Squaric acid dibutylester (Primary)
- Indications Herpes labialis
- Focus Therapeutic Use
- Sponsors Squarex
- 05 Aug 2019 Status changed from active, no longer recruiting to completed, according to a Squarex Media Release.
- 05 Aug 2019 According to a Squarex Media Release, the company plans end of phase II meeting with FDA later this year.
- 05 Aug 2019 Results published in the Squarex Media Release